The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication

The ability of HIV-1 to establish latent infection is a key obstacle to its eradication despite the existence of effective antiretroviral drugs. The brain has been postulated as a reservoir for latent infection, but its role in HIV persistence remains unclear. In this review, we discuss the evidence surrounding the role of the central nervous system (CNS) as a viral reservoir and the potential challenges this might present in eradicating HIV. The strategies for eradication of HIV and their application to latent CNS infection are explored. Finally, we outline new developments in drug delivery and new therapeutic modalities designed to target HIV infection in the CNS.

[1]  B. Ances,et al.  Pathogenesis of HIV in the Central Nervous System , 2010, Current HIV/AIDS reports.

[2]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[3]  M. Churchill,et al.  Use of laser capture microdissection to detect integrated HIV-1 DNA in macrophages and astrocytes from autopsy brain tissues , 2006, Journal of NeuroVirology.

[4]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[5]  D. Fuchs,et al.  Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation , 2014, AIDS.

[6]  R. Price,et al.  An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. , 2014, The Journal of infectious diseases.

[7]  H. Mahajan,et al.  Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting , 2014, Drug delivery.

[8]  E. Thiel,et al.  Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.

[9]  A. Trkola,et al.  HIV rebounds from latently infected cells, rather than from continuing low-level replication , 2008, Proceedings of the National Academy of Sciences.

[10]  J. Glass,et al.  Localization of HIV‐1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry , 1996, Annals of neurology.

[11]  Jessica M. Winkler,et al.  The National NeuroAIDS Tissue Consortium Brain Gene Array: Two Types of HIV-Associated Neurocognitive Impairment , 2012, PloS one.

[12]  J. Mankowski,et al.  Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain , 2013, AIDS.

[13]  M. Churchill,et al.  Is specific HIV eradication from the brain possible or needed? , 2013, Expert opinion on biological therapy.

[14]  D. Moore,et al.  Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy , 2009, Journal of NeuroVirology.

[15]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[16]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[17]  R. Siliciano,et al.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations , 2015, Nature.

[18]  P. Simmonds,et al.  Influence of HAART on HIV-related CNS disease and neuroinflammation. , 2005, Journal of neuropathology and experimental neurology.

[19]  D. Fuchs,et al.  HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. , 2010, The Journal of infectious diseases.

[20]  M. Churchill,et al.  Extensive astrocyte infection is prominent in human immunodeficiency virus–associated dementia , 2009, Annals of neurology.

[21]  R. Siliciano,et al.  Redefining the viral reservoirs that prevent HIV-1 eradication. , 2012, Immunity.

[22]  M. Churchill,et al.  HIV-1 Entry and Trans-Infection of Astrocytes Involves CD81 Vesicles , 2014, PloS one.

[23]  W. Muller,et al.  The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection , 2003, Journal of leukocyte biology.

[24]  J. Clements,et al.  Replication-Competent Simian Immunodeficiency Virus (SIV) Gag Escape Mutations Archived in Latent Reservoirs during Antiretroviral Treatment of SIV-Infected Macaques , 2011, Journal of Virology.

[25]  M. Churchill,et al.  The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes , 2013, PloS one.

[26]  S. Álvarez,et al.  In vivo delivery of siRNA to the brain by carbosilane dendrimer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[27]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[28]  Anitha Rao,et al.  RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma , 2010, Science Translational Medicine.

[29]  D. Richman,et al.  Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.

[30]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[31]  J. Bell,et al.  Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. , 2011, The American journal of pathology.

[32]  R. Siliciano,et al.  A Simian Immunodeficiency Virus-Infected Macaque Model To Study Viral Reservoirs That Persist during Highly Active Antiretroviral Therapy , 2009, Journal of Virology.

[33]  F. Scaravilli,et al.  Detection and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain by polymerase chain reaction/ in situ hybridisation technique , 1999, Acta Neuropathologica.

[34]  L. Epstein,et al.  In situ amplification and detection of HIV-1 DNA in fixed pediatric AIDS brain tissue. , 1996, Human pathology.

[35]  J. Clements,et al.  A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system , 2011, Current opinion in HIV and AIDS.

[36]  Gitte Pedersen,et al.  Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.

[37]  Anthony S. Fauci,et al.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy , 2000, Nature Medicine.

[38]  A. Westfall,et al.  Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients , 2014, AIDS.

[39]  L. Al-Harthi,et al.  Gamma Interferon Primes Productive Human Immunodeficiency Virus Infection in Astrocytes , 2006, Journal of Virology.

[40]  M. Churchill,et al.  Is the central nervous system a reservoir of HIV-1? , 2014, Current opinion in HIV and AIDS.

[41]  C. Yiannoutsos,et al.  Neurovirological Correlation With HIV-Associated Neurocognitive Disorders and Encephalitis in a HAART-Era Cohort , 2013, Journal of acquired immune deficiency syndromes.

[42]  E. Masliah,et al.  Molecular and pathologic insights from latent HIV-1 infection in the human brain , 2013, Neurology.